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ABSTRACT 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor 
proteins. Docking studies are based on several factors. Among 15 entries of PPARγ, 2Q6S was 
taken for docking analysis, as it showed 418 most favored regions, 35 in additionally allowed 
region and none of the residue in disallowed regions. To carry out drug designing, molecules 
were considered from the literature in which substitution of R1 position with dihydrofuryl 
reported to have high dock score (-14.98 Kcal/mol) than the remaining analogues, with better 
geometry and interactions. Hence docking analysis using heteroaryl propionic acid derivatives as 
anti-diabetic agents suggest the reproducibility of active molecules being predicted by 
computational docking studies using Auto dock software. 
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Diabetes mellitus (Type II) is a metabolic disorder which is characterized by 
dysfunctioning of pancreatic beta cells along with insulin resistance, if not controlled leads to 
macro and microvascular disorders1, 2. Dipeptidyl peptidase IV3, GLP-1 analog4, Glucokinase5, 
PPAR (peroxisome proliferated activated receptor) 6 have been identified as potential targets of 
type II diabetes. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear 
receptor proteins. They play essential role in the cellular metabolism of carbohydrates, lipids, 
and proteins, cell differentiation and development7, 8. PPARs function as transcription factors9 
regulating the expression of genes10. These are of three types i.e. alpha (α), delta (beta) (β/δ), 
gamma ( )8. The molecular target of the glitazones was reported to be PPAR-gamma11 which is 
expressed in three forms; they are gamma-1 (γ1), gamma-2(γ2), gamma-3(γ3). The role of PPAR 
in combating diabetes12 has provided us the rationale to carry out structure based drug design 
studies13.  
The selection of protein for docking studies is based upon several factors like, it should 
contain a ligand, structure should be determined by X-ray diffraction, and resolution between 
2.0-2.5 Angstroms and out of the 15 entries of PPARγ, 2Q6S was taken for docking analysis 
(based on the Ramachandran plot statistics) as it showed 418 most favored regions, 35 in 
additionally allowed region and none of the residue in disallowed regions. ISIS draw 2.6, 
AutoDock 3.0 (an automated docking tool) and Web Lab Viewer 4.0 were used as computational 
tools. A graphical user interface called Auto dock Tools, or ADT was utilized to generate grids, 
calculate dock score and evaluate the conformers. 
COMPUTATIONAL TOOLS 
Structural based drug designing:  
Structure-based drug design is one of several methods in the rational drug design toolbox. 
Drug targets are typically key molecules involved in a specific metabolic or cell signaling 
pathway that are known, or believed, to be related to a particular disease state. Drug targets are 
most often proteins and enzymes in these pathways. Molecules are designed to inhibit, restore or 
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otherwise modify the structure and behavior of disease-related proteins and enzymes. Structure-
based drug design uses the known 3D geometrical shape or structure of proteins to assist in the 
development of new drug molecules. 
AutoDock: 
AutoDock is an automated docking tool. It is designed to predict how small molecules, 
such as substrates, bind to a receptor of known 3D structures. AutoDock actually consists of two 
main programs: one performs the docking of the ligand to a set of grids describing the target 
protein; and the other Auto Grid pre-calculates these grids. In addition to using them for docking, 
the atomic affinity grids can be visualized. A graphical user interface called AutoDock Tools or 
ADT was utilized to generate grids, calculate dock score and evaluate the conformers. 
 
 
WeblabViewerlite: 
The WebLab Viewer is an innovative software tool for examining the 3D structure of 
molecular models, and for communicating the resulted information. With the WebLab Viewer, a 
molecule can be viewed as a wireframe, a stick model, a ball and stick model, or a space-filling 
model. The model can be rotated, translated, or scaled to any particular viewpoint.  Distances, 
angles, torsions, and stereochemistry can be easily measured; these variables are instantly 
updated whenever the local geometry is modified.  
MATERIALS AND METHODS 
A total of 15 entries of PPARγ were selected from RCSB protein data bank, based on the 
presence of ligand, x-ray diffraction and 2.0-2.5 Aº resolution. Out of the 15 entries, 2Q6S was 
taken for docking analysis (based on the Ramachandran plot statistics) as it showed 418 most 
favored regions, 35 in additionally allowed region and none of the residue in disallowed regions. 
A comparative protein - ligand dock analysis was performed using 2Q6S extracted from Protein 
Data Bank (PDB) 14 to evaluate the algorithm and scoring function efficiency between AutoDock 
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3.0 and experimental activities. The molecules selected for docking studies are from the selected 
article15, 16.  
All these molecules as well as the bound ligand of the protein 2Q6S were docked by 
using the software AutoDock and the score values are predicted. The protein ligand interactions 
were also studied in web server. Based on the score values against the activity in µM the 
molecules were represented as active, moderately active and inactive. All molecules were drawn 
using Integrated Scientific Information System (ISIS) draw tool and energy minimized using 
Tsar Software. Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 2Q6S binding pocket. To perform the task, the 
powerful genetic algorithm method implemented in the program AutoDock 3.017 was employed. 
All water molecules were removed from the original Protein Data Bank file. Polar hydrogen 
atoms and Kollman charges18 were added. Grid maps were generated by AutoGrid program. 
Each grid was centered at the crystal structure of the corresponding 2Q6S bound ligand 
PLB5001 (B). The grid dimensions were 60 A˚ X 60 A˚ X 60 A˚ with points separated by 0.375 
A˚. For all ligands, random starting positions, random orientations and torsions were used. 
During docking, grid parameters were specified for x, y and z axes as 38.808, 30.946 and 42.249 
respectively.  
 
RESULTS AND DISCUSSION 
Molecules selected from the articles15, 16 were docked using AutoDock software and 
docked scores of those molecules were represented in Table-1, with their activity, number of 
hydrogen bonds and interacting residues. Molecules with high dock scores were selected for 
regression analysis and their docked scores along with their activity, number of hydrogen bonds 
and interacting residues were given in Table-2. The newly designed molecules in Table-3 are 
energy minimized and the resulting molecules are considered for docking analysis using 
AutoDock 3.0 in Linux. Ligand and proteins were prepared. At the end of each run, docked 
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orientations are saved and the resultant molecules are checked for geometry and no of hydrogen 
bonds using web lab viewer software. AutoDock is employed to study the docking molecules 
within active site region of 2Q6S and web lab viewer is used to study the H-bond interaction. 
Docked scores of newly designed molecules are represented in Table-4. 
The newly designed molecules (MOL_NW) were docked against the protein 2Q6S and 
the dock scores were reported in Table-4 above and the following interactions were seen with the 
new ligands and the active sites of the protein. From Table-4, it became evident that the newly 
designed molecules have docked scores more than -12.71kcal/mol, which is the docked score of 
2Q6S. Hence, further proof was provided by plotting a graph (Figure-1) between experimental 
values and dock scores, where it is clear that they represented a correlation of 0.7489. 
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Table 1: The ligands selected for docking studies and their corresponding interaction energies.  
Molecules 
Activity (Ki) in 
µM 
AutoDock score  
(Kcal/mol) 
No. of H-bonds Interacting residues 
1 2.1 -9.16 2 Glu259, Ile281 
2 1.1 -13.12 2 Glu559, Ile281 
3 0.24 -13.53 1 Lys265 
4 8.8 -12.13 1 Phe265 
5 0.36 -12.4 1 Lys265 
6 12.0 -11.93 2 Ser342, Lys265 
7 5.1 -7.73 1 Arg288 
8 0.063 -13.04 1 Lys265 
9 0.15 -13.09 1 Arg288 
10 0.56 -10.83 1 Lys265 
11 14.4 -11.19 1 Glu291 
12 7.98 -12.92 1 Lys265 
13 0.394 -12.88 1 Lys265 
14 3.5 -12.91 3 Arg288, Cys285, Ser289 
15 0.038 -9.44 0 - 
16 17.0 -13.52 1 Lys265 
17 0.081 -13.67 1 Ser289 
18 0.81 -13.05 2 Ile281, Cys285 
19 0.023 -13.42 1 Arg288 
20 0.016 -14.65 1 Ile281 
21 0.052 -12.94 2 Lys367, Cys285 
22 0.011 -13.12 1 Ser342 
23 0.094 -13.74 0 - 
24 0.015 -13.72 0 - 
25 0.017 -13.05 1 Arg288 
26 0.007 -14.6 1 Arg288 
27 0.334 -12.35 3 Ile281, Cys285, Ser289 
28 0.27 -10.9 0 - 
29 0.006 -13.78 2 Gly284, Lys265 
30 0.348 -11.46 1 Ile326 
31 0.073 -12.45 1 Met348 
32 1.6 -12.95 2 Lys265, His266 
33 0.21 -13.61 1 Arg288 
34 1.1 -13.12 0 - 
35 1.1 -11.34 2 His266, Ile281 
36 0.093 -12.59 4 Ile281, Gly284, His266, Lys265 
37 0.3 -13.63 2 Gly284, Lys265 
38 0.02 -13.27 2 Ser289, Cys285 
39 0.043 -12.04 1 Ile281 
40 21.0 -14.09 1 Ile281 
41 0.043 -13.21 2 Arg288, Leu340 
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Table 2: Dock scores of molecules showing experimental activity and computational binding 
energy values for set of molecules under study.  
Molecules 
Activity (Ki) 
in µM 
AutoDock 
score  
(Kcal/mol) 
No. of H-
bonds 
Interacting residues 
8 0.063 -13.04 1 Lys265 
19 0.023 -13.42 1 Arg288 
21 0.052 -12.94 2 Lys367, Cys285 
22 0.011 -13.12 1 Ser342 
24 0.015 -13.72 0 - 
29 0.006 -13.78 2 Gly284, Lys265 
31 0.073 -12.45 1 Met348 
36 0.093 -12.59 4 Ile281, Gly284, His266, 
Lys265 
38 0.02 -13.27 2 Ser289, Cys285 
41 0.043 -13.71 2 Arg288, Leu340 
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Table 3: Newly designed molecules from the basic structure. 
N
O
O N
O
O
R3
R1 R2
 
S.No R1 R2 R3 
1 propyl H propyl 
2 dihydrofuryl H propyl 
3 sulphur H propyl 
4 chlorine H propyl 
5 propyl H propyl 
6 Isopropyl H propyl 
7 bromine H propyl 
8 isobutyl H propyl 
9 H propyl propyl 
10 H sulphur propyl 
11 H chlorine propyl 
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Table 4: Docked scores of newly designed molecules (MOL_NW). 
S.No of 
MOL_NW             
AutoDock score  
(Kcal/mol) 
No. of H-bonds Interacting residues 
1 -13.62 1 Ile326 
2 -14.98 2 Glu343  Arg288 
3 -13.01 3 Glu284  Ile281 Cys285 
4 -13.83 2 Lys265 Gly284 
5 -14.05 1 Ser289 
6 -13.83 2 Gly284 Ser342 
7 -14.0 0 - 
8 -14.92 1 Lys265 
9 -14.43 0 - 
10 -13.71 4 His266 Gly284 Arg280 
Ile281 
11 -13.57 1 His266 
 
Figure 1: Graph plotted between dock scores and activity values of selected molecules from 
Table-2. 
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CONCLUSION 
The RMSD (Root Mean Square Division) observed was reported to be less than 2 Aº with 
respect to 2Q6S bound ligand, justifies the validation of AutoDock software. Inhibitors exhibited 
positive correlation with experimental data where in highly active molecules showed high dock 
score (MOL_NW-2, -14.98 & MOL_NW-8, -14.92) and similar observation was also reported in 
moderately active molecules (MOL_NW-4, -13.83 & MOL_NW-5,-14.05) and least active 
(MOL_NW-3, -13.01 & MOL_NW-11, -13.57). Gly284, His266, Lys265 H-bond interactions 
are represented in most cases. The docking program in auto dock justifies the correlation 
between the experimental values and the values derived computationally. In these newly 
designed molecules with novel analogues, MOL_NW-2 reported to have high dock score (-14.98 
Kcal/mol) than the remaining analogues. In the 2nd molecule R1 position was substituted by 
dihydrofuryl to enhance the features of the designed molecule. Therefore, the dock analysis 
performed in AutoDock suggests the importance of evaluating the prediction accuracy of scoring 
functions adopted in various docking programs. In AutoDock, a positive correlation was 
observed between experimental values and computational dock scores.  
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